A technology to save lives

IV PREV: PREVENTING INFECTIONS

Kanika Bansal

Founder Medicen Devise Limited

Presented to Gabriel

19th September, 2013

1

Infections due to catheters

1 in 4 infected patients die Antibiotic

resistance $6Billion treatment cost

2

2

Existing Solutions

Following precautions as per guidelines

Antiseptic coated catheter

Antiseptic coated dressing

33

Issues with Existing Solution

AsphyxiationIrregular

Dry up quicklyNo Warning

4

Our Solution: IV Prev

•Externally attached to catheter

•Automatically sterilizes area reducing 99.9% skin bacteria

•End-User Feedback: Addenbrookes, Cambridge & Royal Infirmary, Edinburgh

•Patent Filed

5

Competitor Analysis

Products Antiseptic Effect with

time

Antiseptic Used

Lifetime Warning System/Ind

ication

IV Prev Maintains constant

effect

Any off the shelf

Same as patient

stay

Yes

Coated catheter

Declining Specific 7-10 days No

Antiseptic Dressings

Declining CHG only 2-3 days No

6

Initial Target Market for IV Prev 20%

Market Size for IV Prev

Total Addressable Market: 22 Million units in US & Europe/Year

Potential of £1.5 Billion revenue/year in US & Europe

7

Source: US Venous Access Catheter Market, 2010 by Frost & Sullivan

Customers

Catheter Manufacturers

Antiseptic Manufacturers

Hospital Procurement

CR Bards

Covidien

Becton Dickinson

3M

GSK

Systagenix

Teleflex

Influenced by Hospital Procurement Influenced by KOL

8

Option to consider Sub-contract manufacturing and independent medical device distribution route

Route to Market: Licensing Model9

KOL

Feedback

Catheter & Antiseptic Manufacturers

Value Proposition for Customer

• Increased margins by combining anti-infective device with current product

• Have consumables having recurrent sales

• Address key market driver in rapidly growing market

• Global Appeal

• Short Development cycle

10

Value Proposition for User

• Benefits to Hospital Procurement• Easier reimbursement from Medicaid• Less replacement catheters, dressings and

antibiotics leading to reduced cost• Reduced hospital stay of patient

• Benefits to End-User• Reduction in infections• Ease in use• No compromise with sterility of catheter

11

Catheter Selling Price of catheter

Selling Price of IV Prev

Cost saved by IV Prev(If Minimum 10% effective)

Cardiology (Central Venous Catheters)

PICC £220 £44 £64 Million

CVC £150 £30 £312 Million

Urology

Dialysis Catheter

£700 £140 £82 Million

Foley Catheter £10 £10 £185 Million

Intravenous

Ports £1000 £200 £15 Million

Total savings for NHS after removing introduction cost £494 Million

Catheter Segmentation 12

Estimated sub-contract manufacturing cost: £2/ device

Action Plan

Q4-Q5 Q6

Business ModelProduct Development

Completed Q1-Q3

Regulations

Conceptualization Proof of Concept Engagement with end user (KOL) Prototyping Initial biology lab Testing

CE MarkFDA

License to commercial partner

Clinical Study for market traction

Marketing

Customer Engagement

£150k £200k £150k

13

13

Financial Projection 14

Year 2013 2014 2015 2016 2017IV Prev sold 0 0 118k 583k 1000k

Consumables sold

0 0 354k 1896k 3000k

Market Captured

0% 0% 1% 5% 8%

Turnover 0 0 £280,911 £2.79M £6.81M

Upfront Payment

0 0 £250,000 0 0

Overheads £167,636 £181,482 £333,665 £359,180 £384,102

Net Profit/(Loss) (£167,636) (£181,482) £197,246 £2.43M £6.43M

Funding (Net Investment)

Phase 1: £150k Oct 2013- June 2014

SMART Grant (Applied)

£100k Development of soft tooling for final prototype manufacturing, testing for CE Mark, filing of CE Mark and FDA application

Private Funding £50k

Phase 2: £350k July 2014

Private Funding £350 Clinical studies and health economic studies for market traction, PCT and national phase patent maintenance & corporate overheads

15

Team

Founder Director (Kanika Bansal)

MSc Biomechanical Engineering2 years manufacturing & 5 years of designing experience

Advisor/(NXD)(Ian Muirhead)

Expertise in medical device start-upsExperienced in raising funds

Chairman(To be Appointed)

Expertise in clinical studies and marketing of medical products

16

Summary• Annually 250,000 cases of infections in US with a cost of

$6.25 Billion

• IV Prev will reduce infections and healthcare associated costs for infections• $1.5 Billion market to target for IV Prev

• Initiating regulatory and customer engagement

• Next stage will be to conduct clinical evaluation, in parallel will continue customer engagement

• We need to secure £500,000 funding for product development, clinical studies and patent maintenance & corporate overheads • Exit potential through trade sale within 5 years

17